Pharmacotherapy options and drug development in managing periprosthetic joint infections in the elderly

Expert Opin Pharmacother. 2019 Jun;20(9):1109-1121. doi: 10.1080/14656566.2019.1602118. Epub 2019 Apr 14.

Abstract

Introduction: Prosthetic joint infections are an increasingly important problem among patients undergoing arthroplasty procedures, and are associated with significant morbidity, reduced quality of life, substantial healthcare costs, and even mortality. Arthroplasties are performed with increasing frequency in elderly patients, who present specific problems.

Areas covered: Surgical therapy is clearly influenced by the clinical status of the patient, which in some case can contraindicate surgery. Antibiotic selection is also affected by comorbidities and underlying diseases, which in some cases reduce therapeutic options. The authors review this together with the changes in pharmacokinetics and pharmacodynamics in the elderly population and the prospects for future research on prevention and treatment.

Expert opinion: The management of PJI in the elderly makes multidisciplinary teams even more mandatory than in other patients, because the complexity of these patients. A frequent scenario is that in which surgery is contraindicated with long-term suppressive treatment as the only available option. Treating physicians must consider the presence of multiple comorbidities, interactions with other treatments and secondary effects when choosing antibiotic treatment. An in-depth knowledge of the alterations in pharmacokinetics and pharmacodynamics in elderly patients is key for a proper treatment selection.

Keywords: Treatment; antibiotic; elderly; pharmacotherapy; prosthetic joint infection.

MeSH terms

  • Aged
  • Comorbidity
  • Drug Development / methods*
  • Drug Therapy / methods*
  • Humans
  • Prosthesis-Related Infections / drug therapy*
  • Prosthesis-Related Infections / pathology
  • Quality of Life / psychology*